drugset / Trial / NCT05123053

Firdapse for Post-BOTOX Vocal Weakness

NCT05123053

Phase 2 Completed 18 enrolled Augusta University
NaSingle-groupOpen-labelTreatment

Summary

Botox injections into the thyroarytenoid muscle are a predictable and effective treatment for SD, but typically result in transient symptoms of voice weakness and breathiness during the first 2-3 weeks after injection. Investigators hypothesize that voice weakness and breathiness after Botox treatment can be alleviated using amifampridine.

Timeline

Start
2021-10-28
Primary completion
2025-05-27
Completion
2025-09-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Amifampridine Small molecule 10 mg

Indications

No indication recorded.